Sirna Shareholders OK Merck Acquisition; Firm Alters Closing Expectation Date | GenomeWeb
NEW YORK (GenomeWeb News) — Sirna Therapeutics yesterday said its shareholders have approved Merck’s bid to acquire the company.
 
Sirna said the deal, subject to customary closing conditions, is “expected to close as soon as reasonably practicable.” Earlier in December the company said the acquisition “may close as early as this month.” The deal was originally slated to close by the first quarter of 2007.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.